VXRT - Vaxart's COVID-19 vaccine candidate shows encouraging action in preclinical studies

Vaxart ([[VXRT]] -5.2%) has announced topline results from preclinical studies evaluating oral COVID-19 vaccine candidate, demonstrating that all hamster models that received two oral doses of COVID-19 vaccine candidate were protected against systemic weight loss, as well as lung weight gain, which is a key indicator of lung damage due to infectionThe study evaluated Vaxart’s recombinant adenoviral vaccine, and data demonstrated that all unvaccinated animals lost at least 8% of their body weight, and all showed evidence of lung disease as measured by relative weight gain in the lungs. Hamsters receiving one oral dose had partial protection.

For further details see:

Vaxart's COVID-19 vaccine candidate shows encouraging action in preclinical studies